Strategic Partnerships Renovia has already engaged in clinical trial partnerships (e.g., with ObvioHealth) to execute virtual trials, signaling openness to outsourcing and collaborations that can scale trials for new pelvic floor devices or digital therapeutics.

Digital Therapeutic Expansion The company focuses on leva Digital Therapeutic for pelvic floor disorders, presenting a clear opportunity to align with digital health distributors, women's health platforms, and payer-ready solutions seeking non-invasive, tech-enabled care.

Regulatory Momentum FDA Breakthrough Device Designation for leva and ongoing R&D awards indicate strong regulatory and clinical validation, suggesting sales pitches should emphasize faster path to market, reimbursement potential, and clinical efficacy.

Funding & Growth With substantial funding rounds (Series C1 and private equity investments) and a leadership transition in 2021, there is financial runway and growth velocity that can support expanded commercial launches, channel expansion, and incentive-based partnerships.

Market Positioning Operating in a niche of female pelvic floor disorders with a scalable digital health approach and a small headcount signals partner-ready, high-impact collaborations with specialty clinics, DME distributors, and telehealth platforms targeting gynecology and colorectal care.